GLP-1 off-ramp planner
A 12-week transition protocol for adults coming off Ozempic, Wegovy, Mounjaro or Zepbound. Protein floor, strength schedule, sleep, and a taper shape to take to your prescriber.
12
Week window
1.9
g/kg protein floor
3×
Strength per week
If you are currently on a GLP-1, coordinate every dose change with your prescribing physician. This protocol is educational scaffolding to take into that conversation — it is not medical advice and it does not replace clinical care.
Six questions. One honest off-ramp.
The panel asks where you are in the taper, which drug, how long, your weight, what training you are actually doing, and what you want afterwards. It returns your protein floor, a readiness score, and the taper shape to take to your prescriber.
- No email, no account, nothing stored on a server
- Protein floor calculated at 1.9 g/kg of your body weight
- Taper schedule differs for semaglutide and tirzepatide
- Every claim links back to the trial it came from
GLP-1 Off-Ramp
Question 1 of 6
There's no wrong answer here, and staying on is a legitimate one.
What has to take the drug’s place
The medication was doing four jobs at once. Nothing replaces all of them, but these four together cover most of the ground — and they are the same four whether you taper or stay on.
Protein floor
1.8–2.0 g per kg of body weight per day, split across four smaller meals. With appetite still suppressed, protein has to be deliberate at every meal — eggs, dairy, fish, meat, legumes, a shake when the day gets away from you.
Strength training
Three full-body sessions a week. Compound movements — squat, hinge, press, pull — in the 6–10 rep range, with progressive overload. This is the non-negotiable one: it is what decides whether the weight you keep off is fat rather than muscle and bone.
Ultra-processed reduction
Get group 4 food out of the daily rotation before appetite returns, not after. Run the UPF score, find the highest-frequency channel, and replace one anchor meal at a time rather than rebuilding the whole week at once.
Sleep
Seven to nine hours, consistent bedtime, and nothing substantial in the three hours before it. Sleep restriction alone produces prediabetic-grade insulin resistance in healthy adults, which is a poor thing to add on top of a taper.
Daily checklist
Five things, every day
- Hit the protein floor, split across four meals
- Sleep seven hours or more — track it rather than guess
- Walk 8,000+ steps
- Nothing substantial in the three hours before bed
- Strength session, if today is one of the three
It is mechanism, not willpower
The evidence here is unusually clear, and unusually badly communicated to the people taking the drug. Here it is with the papers attached.
STEP 1 extension · Wilding 2022
Appetite returns before anything else does
One year after semaglutide withdrawal, around two-thirds of lost weight had returned and most cardiometabolic improvements had reversed. The drug suppressed appetite pharmacologically; nothing had been built to take over.
Body-composition substudies
A large share of what you lose is lean tissue
Published estimates put lean mass at roughly a quarter to two-fifths of total weight lost on semaglutide. That tissue is metabolically expensive to carry and expensive to rebuild — which is why the training starts before the taper.
Bensignor 2024 · JAMA Netw Open
Bone density moves too
GLP-1 monotherapy was associated with reduced bone mineral density at hip and spine. In the same work, concurrent exercise appeared to prevent it — which is the whole argument for pillar two in one sentence.
And if stopping is not right for you
For some adults — high starting BMI, severe metabolic syndrome, established cardiovascular disease — long-term use is the right call, and the SELECT trial reported roughly a 20% reduction in cardiovascular events in adults with obesity and existing cardiovascular disease. Stopping is not a moral achievement. If you stay on, build the same four pillars anyway: the muscle argument does not care whether you taper.
Sources
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
Wilding JPH et al. · Diabetes, Obesity and Metabolism · 2022
PubMed 35441470Body composition and cardiometabolic effects of GLP-1 receptor agonists: changes in lean mass
Linge J et al. · Obesity Reviews · 2024
PubMed 38605467Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment
Jensen SBK et al. · JAMA Network Open · 2024
PubMed 38904957Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
Wilding JPH et al. · New England Journal of Medicine · 2021
PubMed 33567185Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Jastreboff AM et al. · New England Journal of Medicine · 2022
PubMed 35658024Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff AM et al. · New England Journal of Medicine · 2023
PubMed 37952131Scaffolding first. Dose second.
The most common mistake is reversing this order — dropping the dose and then trying to build habits into a returning appetite. Every dose change below belongs to your prescribing physician, not to this page.
Build the scaffolding while the drug still works
Protein floor in place every day. Three strength sessions a week, starting lighter than your ego wants. No dose change yet — you are proving the habits hold before you remove the appetite suppression.
First dose reduction, with your prescriber
One dose level down for semaglutide, or 2.5–5 mg for tirzepatide, agreed with the physician who prescribed it. Hunger returns unevenly. Protein and sleep are what carry this stretch; do not add a calorie deficit on top of it.
Second reduction and the maintenance handover
The strength work should now be progressing rather than surviving. This is where the protocol stops being a taper plan and becomes how you eat and train — which is the only version that outlasts the prescription.
Straight answers
Coming off a GLP-1
Because the drug was doing the appetite work, and when it stops, appetite comes back — often to a body that is now defending a lower weight with less lean mass and altered hunger signalling. The STEP 1 trial extension documented that around two-thirds of lost weight returned within a year of withdrawal, and most cardiometabolic improvements went with it.
That is a mechanism, not a character flaw, which is exactly why the fix has to be structural. Something has to take the drug's place in the system: protein that blunts hunger, training that protects the tissue, sleep that keeps insulin sensitivity from sliding, and a food environment that is not working against you.
Of lost weight regained by 1 year (STEP 1 extension)
Follow-up period in that extension
Length of this off-ramp protocol
Educational only. Never adjust or stop a prescribed medication based on a web tool — coordinate every change with your prescribing physician.
The drug was never the whole plan
The assessment looks at your markers, your history and what you have already tried, then points you at the protocol the research supports for your profile — whether that includes the medication or not.
Educational only, not medical advice. This planner produces an estimate and a structured protocol, not a diagnosis or a prescription. Never adjust, taper or stop a prescribed medication without your prescribing physician. These statements have not been evaluated by the Food and Drug Administration. Individual results vary; no outcome is guaranteed.